AIM ImmunoTech Inc. announced the promotion of Christopher McAleer, Ph.D., from Deputy Scientific Officer to Scientific Officer. Prior to joining the Company in June 2022, Dr. McAleer held positions at Hesperos Inc. In his most recent role at Hesperos, Principal Scientist, he was responsible for leading teams in higher throughput operations projects as well as prototype projects including both NIH-funded and industry-sponsored which included studies of neuromuscular disorders, human complement pathways, cardiac dysfunction, liver metabolism and PKPD modeling, M/NAFLD, sarcopenia, and metabolic syndrome, and autoimmune diseases. Prior to his appointment as Principal Scientist, he served as Senior Scientist from 2016-2019 where he led a team to build a multi-organ MPS-based model using human and rat primary and iPSC derived tissues to study interspecies differences of drug toxicity.

Additionally, as Senior Scientist he was responsible for writing in full or in part 7 funded NIH SBIR grant proposals as well as executing 4 contracts for private client partners resulting in repeat business from all 4 clients totaling approx. $1.3 million. Additionally, Dr. McAleer has authored published manuscripts in several peer-reviewed science and nature journals, book chapters and scientific conference publications.

His manuscript titled Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics published in Science Translational Medicine in December 2019 had the distinction of being featured by then-NIH director Francis Collins weekly blog. Dr. McAleer received his Bachelor of Science Education in Biology and Chemistry degrees from West Chester University of Pennsylvania, and his Masters in Molecular Biology and Microbiology as well as his Doctorate in Biomedical Sciences from University of Central Florida. He completed his post-doctoral research at the University of Central Florida.